preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
Vyhledat
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Perceived burden of COPD is higher for younger patients
New global survey reveals perceived burden of disease is greater in younger people living with COPD
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Oznámení o ochraně osobních údajů
Zásady ochrany soukromí
Zásady ochrany osobních údajů pro zdravotnické odborníky
Zásady ochrany osobních údajů pro zdravotnické odborníky
Obchodní podmínky
Obchodní podmínky pro nákup Boehringer Ingelheim spol. s r.o.